

Supplementary Data

SUPPLEMENTARY TABLE S1. DEMOGRAPHICS

	<i>Acute phase</i>		<i>Extension phase ATX (n = 155)</i>
	<i>ATX (n = 120)</i>	<i>PLB (n = 89)</i>	
Age (years), mean (range)	12.2 (10.0–16.8)	12.4 (10.1–17.0)	12.3 (10.0–17.0)
Gender (male), <i>n (%)</i>	74 (61.7)	55 (61.8)	91 (58.7)
Ethnicity, <i>n (%)</i>			
African American	13 (10.8)	11 (12.4)	11 (7.1)
White	86 (71.7)	66 (74.2)	121 (78.1)
Eastern Asian	2 (1.7)	1 (1.1)	3 (1.9)
Hispanic	18 (15.0)	11 (12.4)	19 (12.3)
West Asian	1 (0.8)	0	1 (0.6)
ADHD subtype, <i>n (%)</i>			
Hyperactive/impulsive	2 (2.0)	2 (3.0)	3 (2.3)
Inattentive	49 (49.5)	36 (53.7)	65 (50.8)
Combined	48 (48.5)	29 (43.3)	60 (46.9)
Prior stimulant exposure, <i>n (%)</i>	42 (35.0)	23 (25.8)	43 (27.7)
ADHD-only, <i>n (%)</i>	27 (22.5)	0	21 (13.5)
Dyslexia-only, <i>n (%)</i>	29 (24.2)	29 (32.6)	38 (24.5)
ADHD+D, <i>n (%)</i>	64 (53.3)	60 (67.4)	96 (61.9)

ADHD, attention-deficit/hyperactivity disorder; ADHD+D, attention-deficit/hyperactivity disorder+dyslexia; ATX, atomoxetine; PLB, placebo.